Hers vs Medvi: Subscription Telehealth and Compounded Care

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

The following is independent editorial analysis. PlexusDx has no commercial relationship with Hers or Medvi, and this page carries no affiliate links or sponsored placements.

Hers and Medvi reach the same GLP-1 medications through very different front doors — one a polished consumer subscription brand, the other a compounded-pharmacy program. For readers weighing the two, the useful comparison is less about the drug and more about the experience, the model, and what both leave out. As of April 2026, each is one option among dozens in this market.

Two different front doors to GLP-1 care

Both routes end at a provider-issued GLP-1 prescription, but the packaging around that prescription differs sharply. Hers is built as a branded, membership-style consumer experience with a recognizable interface and marketing polish; Medvi is structured around its compounding pharmacy pipeline, where the pharmacy relationship is the product. Neither structure changes the medication — it changes how you sign up, how you pay, how quickly you get answers, and how the ongoing relationship feels day to day.

Inside the Hers subscription model

Hers (part of Hims & Hers Health) operates as subscription telehealth: a virtual clinical evaluation, provider-issued prescriptions, and dispensing of either brand-name FDA-approved GLP-1 therapy or compounded semaglutide and tirzepatide through licensed compounding pathways. Its weight-loss program details are posted at Hers's official website.

Inside Medvi's compounded-pharmacy model

Medvi (Medvi Wellness) runs a telehealth-plus-compounded-pharmacy structure, with program specifics, medication options, and pricing that shift over time. The current terms on Medvi's official website are the reliable source at the moment you read this. Across the category, monthly totals commonly land in the $200—$700+ range once program fees and dispensing are included.

What the clinical trials actually measured

Under both brands sits the same compound class. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide act on appetite and satiety signaling and slow gastric emptying. The evidence rests on STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Those trials measured molecules, not brands, and their reported effect sizes reflect compound and dose rather than the subscription wrapper a program builds around them. A polished onboarding does not add to the clinical record.

The upstream biology neither brand maps

A subscription sign-up does not read your genetics. Variants in FTO, GLP1R (the receptor every GLP-1 compound targets), MC4R, and TCF7L2 shape the appetite, satiety, and glucose-handling biology that sits under any protocol. These are pathway-level markers, not drug-response predictors, but they add real context. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across those genes.

A genetics-first alternative from PlexusDx

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with the genetic read built in. It is the "test before you invest" step a subscription checkout skips.

Not affiliated: PlexusDx has no commercial ties to Hers or Medvi and received no compensation for this review.

Related reading on PlexusDx: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers or Medvi and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

Is Hers a subscription or a one-time purchase?

Hers operates as subscription telehealth, meaning ongoing membership-style access to virtual care and dispensing rather than a single transaction. Medvi is structured around its compounding pharmacy program. Both bill on a recurring basis, and current terms are posted on each brand's own website.

Do Hers and Medvi offer the same GLP-1 medications?

Both can prescribe GLP-1 receptor agonists through telehealth and may offer compounded semaglutide or tirzepatide, with brand-name options depending on the program. The specific doses and formats differ and change over time, so verify the current medication menu on each site.

Does the Precision Peptide Genetic Test replace a consultation?

No. It does not diagnose, prescribe, or predict response to any medication. It maps pathway-level variants in FTO and MC4R, and TCF7L2 to give you baseline context, which you then bring to a qualified healthcare provider before starting any protocol.

Why choose PlexusDx over a subscription brand?

PlexusDx pairs semaglutide and tirzepatide with an upstream genetic read that most subscription checkouts skip entirely. The pathway-level insight on FTO, MC4R turns a routine sign-up into an informed decision, letting you enter the conversation with a provider armed with context rather than defaulting into an enrollment flow.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education